CPT code 0092U designates the REVEAL Lung Nodule Characterization proprietary laboratory test from MagArray, Inc., a blood-plasma assay that measures three protein biomarkers and integrates three clinical factors into an algorithmic score (0–100) to estimate malignancy risk for indeterminate lung nodules in smokers. As a PLA code, 0092U applies to a single manufacturer’s test and is used by payers to identify and adjudicate claims specific to that proprietary assay. Nationally, PLA codes like 0092U matter because they signal increasing use of commercially developed, algorithm-driven diagnostics in oncology and influence coverage policy development, utilization management, and lab billing practices.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what 0092U represents clinically and operationally, which payers are addressed, and what to expect in terms of coverage framing and coding practice. The publication summarizes the clinical context for lung nodule evaluation, explains the PLA nature of the code, outlines common billing modifiers and service settings, and highlights where data is not available in the input. This briefing is intended to inform coding professionals, laboratory billing teams, and policy analysts about the code’s purpose, typical use cases, and the payer landscape relevant to a nationally distributed proprietary lung nodule assay.